We and others have shown that while most solid tumors including CRC do not respond to MCL1 inhibition, combined inhibition of MCL1 and BCL-XL is very potent, suggesting that high levels of BCL-XL deter the efficacy of MCL1 inhibition alone [24, 25, 29, 45]. Here, BCL2L1 is linked to colorectal carcinoma.